198P Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial

肿瘤科 医学 肺癌 阶段(地层学) 内科学 生物 古生物学
作者
Ying Cheng,Hui Wang,X. Min,Dong Hu,Q-M. Wang,B. Li,Aimin Liu,Chunyu Liu,Lingdi Zhao,Ying Liu,Chun‐Ming Wu,Xin Yan,X.-C. Zhang,Huijuan Cui,Jian Zhang,Kang Ma,Ling Yang
出处
期刊:ESMO open [Elsevier BV]
卷期号:9: 102771-102771 被引量:2
标识
DOI:10.1016/j.esmoop.2024.102771
摘要

cCRT is the standard of care in LS-SCLC, but LS-SCLC still represents a significant unmet medical need with a median survival of 25 to 30 mo. Addition of the anti-PD-L1 antibody adebrelimab to carboplatin and etoposide has demonstrated survival benefits in extensive-stage SCLC in the phase 3 CAPSTONE-1 trial. This ongoing, 2-stage, phase 3 study aims to evaluate cCRT with adebrelimab in LS-SCLC. In the safety run-in stage, patients with pathologically confirmed, unresectable LS-SCLC were enrolled. Treatment consisted of four 3-week cycles of adebrelimab (20 mg/kg, iv, d1, Q3W) plus carboplatin (AUC 5, iv, d1, Q3W) and etoposide (100 mg/m2, iv, d1, 2, 3, Q3W), with thoracic radiotherapy started on cycle 3 (60 Gy/2 Gy, QD, 6 weeks). Following cCRT, patients received maintenance adebrelimab (20 mg/kg, iv, Q3W) until disease progression or unacceptable toxicities. The primary endpoint was safety. In the safety run-in stage, 28 patients were enrolled and all received adebrelimab with cCRT. As of Oct. 31, 2023, median follow-up was 29.4 mo (range 6.5-33.3). Grade ≥3 TRAEs occurred in 27 (96.4%) patients; all events with an incidence of ≥10% were hematological toxicities. Four (14.3%) patients had treatment-related pneumonitis and one (3.6%) had treatment-related immune-mediated lung disease (all grade 2). TRAEs led to treatment discontinuation in one (3.6%; infusion-related reactions) patient. There were no deaths due to TRAEs. Confirmed ORR was 92.9% (26/28; 95% CI 76.5-99.1) and DCR was 100% (28/28; 95% CI 87.7-100). Among responders, median DoR was 20.1 mo (95% CI 7.7-not reached [NR]; 11/26 responses ongoing). Median PFS was 17.9 mo (95% CI 8.8-NR). Median OS was NR and the OS rate at 2 years was 64.3% (95% CI 43.8-78.9). In the safety run-in stage, adebrelimab with cCRT showed acceptable tolerability and favorable efficacy outcomes in LS-SCLC. The randomized, double-blind, placebo-controlled stage of the trial is ongoing to further assess the regimen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yihaiqin完成签到 ,获得积分10
1秒前
轩辕剑身完成签到,获得积分0
1秒前
coolkid完成签到 ,获得积分0
2秒前
你怎么那么美完成签到,获得积分10
2秒前
游艺完成签到 ,获得积分10
5秒前
冬月完成签到 ,获得积分10
5秒前
薛乎虚完成签到 ,获得积分10
6秒前
7秒前
大胖完成签到,获得积分10
7秒前
野火197完成签到,获得积分10
11秒前
12秒前
量子星尘发布了新的文献求助10
15秒前
April完成签到,获得积分10
15秒前
周舟完成签到 ,获得积分10
18秒前
V_I_G完成签到 ,获得积分10
19秒前
nick完成签到,获得积分10
20秒前
高高高完成签到 ,获得积分10
23秒前
彪壮的亦瑶完成签到 ,获得积分10
24秒前
科研通AI2S应助科研通管家采纳,获得10
26秒前
Perry应助科研通管家采纳,获得60
26秒前
Akim应助科研通管家采纳,获得10
26秒前
鱼雷完成签到,获得积分10
27秒前
廿伊发布了新的文献求助10
29秒前
我是125完成签到,获得积分10
31秒前
依人如梦完成签到 ,获得积分10
32秒前
33秒前
PDIF-CN2完成签到,获得积分10
37秒前
雪雪完成签到 ,获得积分10
38秒前
39秒前
Willow完成签到,获得积分10
42秒前
研研研完成签到,获得积分10
43秒前
大橙子发布了新的文献求助10
45秒前
dejiangcj完成签到 ,获得积分10
46秒前
无味完成签到,获得积分10
47秒前
大气的尔蓝完成签到,获得积分10
48秒前
科研通AI5应助普鲁卡因采纳,获得10
49秒前
略略略完成签到 ,获得积分10
51秒前
zqlxueli完成签到 ,获得积分10
55秒前
无语的断缘完成签到,获得积分10
57秒前
hdx完成签到 ,获得积分10
58秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022